🚀Enjoy a 7-Day Free Trial Until Jul 20, 2024!

RI

Rigel Pharmaceuticals IncNASDAQ RIGL Stock Report

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is RIGL undervalued compared to its fair value?

The fair value of RIGL stock is hidden USD. Relative to the market price of 9.98 USD Rigel Pharmaceuticals Inc is hidden.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 155 full-time employees. The company went IPO on 2000-...[More about valuation]

Rigel Pharmaceuticals Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.169 $B

Price:

9.98 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.047

FINANCIALS

Rigel Pharmaceuticals financial for reporting period

Income Statement

0.03 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.007 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0082 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.03 B 100%
0.028 B 93%
-0.007 B -24%
-0.0082 B -28%

Balance Sheet

0.13 B
-0.032 B


Financial Position Analysis

Assets

0.13 B
Current Assets
0.092 B
Total non-current assets
0.034 B

Total current liabilities
0.073 B
Total non-current liabilities
0.085 B

Cash Flow Statement

-0.0052 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.005 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Rigel Pharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability score


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-89 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-17 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is RIGL attractive for investment based on fundamental analysis?

RIGL stock rating is hidden. Rigel Pharmaceuticals is a hidden by Eyestock methodology.

Get RIGL Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-16

Gross Margin:

93

CFO / Debt ratio:

hidden

Current ratio:

1.772

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

RIGL analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for RIGL to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Rigel Pharmaceuticals Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Rigel Pharmaceuticals Inc dividends

RIGL dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About RIGL stock

About the company Rigel Pharmaceuticals Inc

Market cap $B

0.169

Dividend yield

Shares outstanding

173.653 B

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 155 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The firm's lead product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its product also includes REZLIDHIA (olutasidenib) capsules, which are for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Its other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development. In addition, it has product candidates in clinical development with partners BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi).

RIGL profile

  • Ticker

    RIGL

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    29 November 2000

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    155

  • City

    South San Francisco

  • Address

    1180 Veterans Blvd

  • Cusip

    766559603